Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Carboplatin 23Paclitaxel 14pembrolizumab 8liposomal doxorubicin 7Bevacizumab 5Specimen Handling 4Cyclophosphamide 4olaparib 3niraparib 3epacadostat 3Topotecan 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Biopsy 3sarilumab 2rucaparib 2poly ICLC 2durvalumab 2cemiplimab 2STA 9090 2Injections 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 2Cisplatin 2veliparib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × paclitaxel poliglumex × Clear all
NCT00017017 2013-05-30

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡